Abstract
Although anlotinib, a multi-targeted receptor tyrosine kinase inhibitor has been reported have antitumor effects in many preclinical and clinical trials, little is known about its effect on hepatocellular carcinoma (HCC). Here, we have shown the antitumor effects of anlotinib on HCC. Data indicated that anlotinib application significantly inhibited HCC cell viability, proliferation, colony formation, and prompted apoptosis in vitro. Furthermore, animal experiments also illustrated that anlotinib alleviated HCC progression. Mechanically, we demonstrated that anlotinib treatment downregulated the anti-apoptotic protein Bcl-2 and Survivin, but upregulated pro-apoptotic molecule Bax, which accounts for its therapeutic effect on HCC. Pathway analysis has shown decreased phosphorylation levels of Erk and Akt. Together, this study suggests that anlotinib may have a direct antitumor progression effect on HCC by inhibiting Bcl-2 and Survivin expression, promoting Bax expression via inactivating Erk and Akt pathways and could be a promising agent treating HCC.
Citations
Mar 18, 2020·Cancer Medicine·Zhi-Ming WangYu-Hong Zhou
Jan 17, 2020·Animal Models and Experimental Medicine·Huiwei SunJun Hou
Sep 19, 2020·Cell Death & Disease·Liguo YangYi Ding
Oct 30, 2019·The Journal of Pharmacy and Pharmacology·Hao RuanCheng Yang
Feb 14, 2019·Journal of Experimental & Clinical Cancer Research : CR·Lijun LiangXiaodong Jiang
Jan 18, 2019·Clinical Epigenetics·Chao HeYongqiang Hao
Jun 18, 2020·Cancer Management and Research·Haoyue HuLi Wang
Jan 27, 2019·Cell Death & Disease·Chao HeYongqiang Hao
Jul 2, 2020·Cancer Management and Research·Qian YangQinglian Wen
May 24, 2020·Medicine·Li SunShangli Cai
Jul 28, 2020·Cell Death & Disease·Fei SongXin-Rong Yang
Jul 23, 2020·Anti-cancer Drugs·Hui LiYing Cheng
Oct 30, 2020·Drug Delivery·Qin GaoSheng Lin
Nov 28, 2020·Drug Development Research·Fan ZhangXuewen Wang
Feb 1, 2020·Medical Hypotheses·Chen ChuXiaochun Zhang
Mar 23, 2021·Frontiers in Cell and Developmental Biology·Xi ZhangZewen Song
Mar 30, 2021·Frontiers in Oncology·Qin GaoSheng Lin
Apr 8, 2021·Hepatology International·Yongkun SunKan Liu
Jun 8, 2021·Frontiers in Oncology·Shenglong Li
Aug 3, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Yuan CaiSong-Ren Yu
Jul 28, 2021·Redox Biology·Zhijian JinLiping Su
Sep 1, 2021·Journal of Clinical Laboratory Analysis·Shanshan FanGuangyu An
Nov 19, 2021·PloS One·Jiangang BiPing Xu
Aug 14, 2021·Anti-cancer Drugs·Shuyi LiSuxia Luo
Jul 20, 2020·Anti-cancer Agents in Medicinal Chemistry·Xiali TangQingyong Chen
Jan 9, 2022·Cancer Chemotherapy and Pharmacology·Peng XuChulei Deng